Shots:

• The first participants have been dosed in a P-I trial of AZD7442 to assess safety- tolerability- and PK of the combination mAbs in up to 48 healthy participants aged 18-55 yrs. in the UK. The study is funded by DARPA
• If AZD7442 proves to be tolerated and has a favorable safety profile in the trial- AstraZeneca will progress it into larger P-II & P-III trials to evaluate its efficacy as a preventative and treatment approach against COVID-19. The company anticipates the results of P-I study in H2’20
• AZD7442 is a combination of two mAbs derived from convalescent patients with SARS-CoV-2 infection- discovered by Vanderbilt University Medical Center and licensed to AstraZeneca in Jun’2020. AstraZeneca optimized the mAbs with half-life extension and reduced Fc receptor binding

 Ref: AstraZeneca | Image: Outsourcing Pharma